A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer Who Have a BRCA1, BRCA2 or PALB2 Mutation

May 19, 2022
Pancreatic Cancer
Hollis Walker, MD
Edward Cancer Center - Naperville
Edward Cancer Center - Plainfield
Nancy Knowles Cancer Center - Elmhurst

This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.



  • Must have successfully undergone a curative intent surgical resection and must have no evidence of recurrent disease
  • No neuroendocrine tumors
  • Must have a mutation in BRCA1, BRCA2, or PALB2 
  • Must not have had progression while receiving platinum-based therapy
  • No personal history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). 
10 years
Accepting Participants
Meribeth Siatta, MSN